PFE - Pfizer announces positive topline phase 3 results for litfulo in patients with nonsegmental vitiligo - Pfizer announces positive topli

PFE - Pfizer announces positive topline phase 3 results for litfulo in patients with nonsegmental vitiligo - Pfizer announces positive topline phase 3 results for litfulo in patients with nonsegmental vitiligo - Litfulo phase 3 studies meet Co-primary endpoints at week 52 in vitiligo - Litfulo safety profile in nsv consistent with prior data; no new safety signals - To submit global regulatory filings for litfulo in nonsegmental vitiligo - More patients on litfulo achieve f-vasi75 and T-vasi50 at week 52 versus placebo